APA (7th ed.) Citation

M, S., & DSP, T. (2026). Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(13), 2525. https://doi.org/10.1158/1078-0432.CCR-26-0534

Chicago Style (17th ed.) Citation

M, Sachdeva, and Tan DSP. "Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 32, no. 13 (2026): 2525. https://doi.org/10.1158/1078-0432.CCR-26-0534.

MLA (9th ed.) Citation

M, Sachdeva, and Tan DSP. "Returning to PARP Inhibition: Rechallenge with Bevacizumab in Ovarian Cancer." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 32, no. 13, 2026, p. 2525, https://doi.org/10.1158/1078-0432.CCR-26-0534.